Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective. Here we reveal that MUC13, a cell surface mucin glycoprotein, is aberrantly expressed by most renal cell carcinomas, with increasing expression positively correlating with tumor grade. Importantly, we demonstrated that high MUC13 expression was a statistically significant independent predictor of poor survival in two independent cohorts, particularly in stage 1 cancers. In cultured renal cell carcinoma cells MUC13 promoted proliferation and induced the cell cycle regulator, cyclin D1, and inhibited apoptosis by inducing the anti-apoptotic proteins, BCL-xL and survivin. Silencing of MUC13 expression inhibited migration and invasion, and sensitized renal cancer cells to killing by the multi-kinase inhibitors used clinically, sorafenib and sunitinib, and reversed acquired resistance to these drugs. Furthermore, we demonstrated that MUC13 promotion of renal cancer cell growth and survival is mediated by activation of nuclear factor jB, a transcription factor known to regulate the expression of genes that play key roles in the development and progression of cancer. These results show that MUC13 has potential as a prognostic marker for aggressive early stage renal cell cancer and is a plausible target to sensitize these tumors to therapy.
Introduction
Renal cell carcinoma (RCC) comprises approximately 4% of all cancers, but an alarming increase in incidence has been reported, 1 with an estimated 338,000 new cases and 102,000 deaths annually. 2 The main histologic subtype, clear cell RCC (ccRCC), accounts for 75% of all cases. 3 Approximately 30% of RCC patients present with metastatic disease at the time of diagnosis and nearly half of the remainder will subsequently develop, and ultimately die from, metastasis. 4 Major clinical challenges for RCC are the lack of a screening method for early-stage diagnosis, the lack of biomarkers for prediction of progression, the frequent development of metastatic disease to the lung, lymph nodes, bone, liver and brain, and the lack of efficacy of therapy for metastatic disease because of inherent or developing drug resistance. RCC is poorly responsive to chemotherapy due to the development of multi-drug resistance. Antiangiogenic agents, tyrosine kinase inhibitors such as sorafenib and sunitinib which affect both angiogenesis and tumor growth and survival pathways, and immunotherapy are the major current approaches for patients with advanced RCC. Unfortunately, while 10-20% of patients have tumors that are initially refractory to therapy, a large majority relapse after a median of 10-12 months. 5 Recently, a definitive phase 3 trial found that sorafenib or sunitinib provided no disease-free survival benefit compared to placebo despite substantial toxicity. 6 Taken together, there is a great need to identify new diagnostic and prognostic markers, as well as developing novel therapeutic strategies for treatment of advanced RCC.
Mucins are complex cell surface and secreted glycoproteins that provide protection and lubrication to the epithelial surface of mucosal tissues. [7] [8] [9] Alterations in the expression and glycosylation of cell surface mucins occur in multiple types of adenocarcinoma. The advantage of their expression in these cancers is likely linked to their functions in healthy tissue, promoting epithelial resistance and resilience to toxic challenges at mucosal surfaces. 9 Carcinoma cells derived from epithelia overexpress mucins to exploit their role in promoting growth, survival, migration and invasion of cancer cells. 8, 9 Mucins have thus been identified as markers of poor prognosis 10, 11 and as attractive therapeutic targets [12] [13] [14] [15] [16] [17] [18] [19] in many cancers. The MUC13 cell surface mucin is overexpressed in gastric, 20 colorectal, 21-23 pancreatic, 24, 25 and ovarian 26 cancers.
Normally this protein is expressed on the apical borders of epithelial cells of the intestine, including the luminal surface glycocalyx of enterocytes and goblet cells in the small and large intestine, 27 with increased cytoplasmic expression seen in response to infection 28 and inflammation. 29 MUC13 has a relatively short 151-amino acid extracellular domain compared to other cell surface mucins, three epidermal growth factor (EGF)-like domains, one sea urchin sperm protein enterokinase arginine (SEA) domain within an extracellular component, followed by a short 23-amino acid transmembrane domain and a 69-amino acid cytoplasmic domain that includes eight serine and two tyrosine residues for potential phosphorylation. In addition, there is a protein kinase C consensus phosphorylation motif 27 that could play a role in cell signaling pathways and promote proliferation and cell survival. 22, 26, 27, 29 Recently, we reported that cytoplasmic MUC13 expression is elevated in high grade and metastatic colorectal cancer, and that MUC13 promotes activation of nuclear factor jB (NFjB), is anti-apoptotic, 30 and pro-inflammatory 31 - rendering MUC13 a potential therapeutic target. 30 However, the functional significance of MUC13 in renal neoplasms has not been defined, and therefore its potential prognostic and therapeutic significance in RCC remains unknown. In our study, we set out to investigate the biological and clinical relevance of MUC13 and its tumorigenic properties in RCC, aiming to develop better treatments for this cancer.
Materials and Methods

Clinical samples
A total of 244 patients from 5 distinct cohorts were used for our study. The clinical data are presented in Supporting Information Technologies) with 10% heat inactivated fetal calf serum, 100 mg/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. All the cell lines have been tested for their STR DNA profiling and the origin and identity of the cells have been confirmed. Two siRNAs (#1 is a SMART pool and #2 is a distinct individual siRNA against the target sequence CUCAGCU-GAUGCUGUAACA) targeting MUC13 and non-targeted control siRNA were purchased from Dharmacon (Dharmacon Research, Lafayette, CO). Oligonucleotide transfection What's new? New prognostic markers and therapeutic targets are needed for renal cell carcinoma (RCC). Here, the authors show that cell surface mucin glycoprotein MUC13 is aberrantly expressed in RCC and associated with poor survival. In cultured RCC cells, MUC13 promotes growth and blocks apoptosis. Silencing of MUC13 expression inhibits migration and invasion, sensitizes renal cancer cells to killing by the multi-kinase inhibitors used clinically (sorafenib and sunitinib) and reverses acquired resistance to these drugs. Thus, MUC13 has potential as a prognostic marker for aggressive early stage renal cell cancer and emerges as a plausible target to sensitize these tumors to therapy. 
Immunohistochemistry
The expression of MUC13 was analyzed by immunohistochemistry (IHC) with the anti-MUC13 polyclonal antibody -R20C1 (dilution, 1:400). 27 The specificity of this antibody for MUC13 staining was described previously. 21, 27, 30 The stained slides were scored by a histopathologist (RL) separately in both the cytoplasm and cell membrane according to a subjective scoring systems as follows: the proportion of positive cancer cell staining was graded 0 (negative), <25% (11), 25-50% (21), 50-70% (31) and >75% (41); and the staining intensity of cancer cells was graded as weak (11), moderate (21), strong (31) or very strong (41). The proportion and intensity scores were added to give an overall staining score for each cellular location.
Growth curves and cell viability assay
Cells (5,000 or 7,500 cells/well) were plated in a 96-well image lock plate (ESSEN BioSCIENCE, Ann Arbor, MI) and visualized using a real-time cell imaging system (IncuCyte live-cell ESSEN BioSCIENCE). Growth curves were built from confluence measurements acquired during round-theclock kinetic imaging. Cell viability was determined using MTT assays.
Migration assays
The in vitro cell migration rates of cells were established using the IncuCyte. Before experiments, cells were treated under the indicated conditions for 18 hr. Cell migration was assessed by wound healing scratch assays, in which, RCC cells were grown to confluence and then a scratch was made using a 96-pin Wound Maker (ESSEN BioSCIENCE). The wells were washed with PBS to remove any debris and incubated in the absence of the treatment with culture medium. Wound images were automatically acquired and registered by the IncuCyte software system. Typical kinetic updates were recorded at 2 hr intervals for the duration of the Experiment (48 hr). The data were then analyzed using an integrated metric. Relative wound density was used as an indicator for wound closure.
Transwell invasion assay
Cells were seeded on the top of inserts containing an 8 lm pore size PET membrane with a thin layer of a Matrigel basement Membrane Matrix (Corning, Bedford, MA) at 4.0 3 10 4 cells/well without serum. RPMI (600 ll) with 10% FBS was added to the lower chamber as chemoattractant. The plates were then placed in an incubator at 378C with 5% CO2 for 24 hr. After incubation, the cells remaining in the upper chamber were carefully removed, and the transwell membrane was fixed with 100% methanol and stained with 0.5% crystal violet. To count the fixed cells, images were captured randomly from 5 fields of vision at 3200 magnification.
Cell death assays
Cells were collected and incubated with LIVE/DEAD fixable dead cell stains detection kit (Life Technologies) following the manufacturer's instructions and analyzed by by Cyto-FLEX flow cytometry (Beckman Coulter, Brea, CA) using the Flowjo v10 software (Flowjo, LLC, Ashland, OR).
Immunoblot analyses
Sub-confluent cells were collected, washed with cold PBS, and harvested with cell lysate buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1.0% Triton X-100, 1x Complete protease inhibitor mixture, 2 mm sodium vanadate, 10 mm sodium fluoride). The resulting lysates were used for immunoblot analyses as described previously. 30 
Statistical analysis
Statistical analyses were performed using Prism v5 (GraphPad Software, La Jolla, CA). The statistical test used and the sample sizes for individual analyses are provided within the figure legends. Statistical significance was set at p < 0.05.
Additional information is described in Supplementary Materials and Methods.
Results
Clinical study participants
A total of 244 patients from 5 distinct cohorts were included for our study (clinical data presented in Supporting Information Table 1 ). Histologic diagnoses and tumor grading of hematoxylin and eosin-stained tissue sections were assessed according to the World Health Organization Classification of Tumours. 32 The original grading of the tumor was used for statistical purposes throughout our study, rather than the features of the individual tumor core.
MUC13 expression is associated with aggressive clear cell RCC
We initially analyzed the expression profile of MUC13 by immunohistochemistry (IHC) from matched non-diseased and malignant kidney tissue. In this series of 10 ccRCC and adjacent uninvolved tissue sections (patient cohort 1), MUC13 protein expression was greater in 100% of tumors compared to adjacent non-diseased kidney (Fig. 1a) . In the
Tumor Markers and Signatures
Sheng et al. normal kidney, MUC13 expression was restricted to the distal convoluted tubules and collecting ducts (Fig. 1a , Supporting Information Fig. 1A ) and these cells exhibited uniform, membranous and cytoplasmic staining with apical polarity (Fig.  1a, Supporting Information Fig. 1A ). No positive staining was seen elsewhere in the cortex: in particular, the glomeruli, Bowman's capsule and the proximal convoluted tubules were negative (Fig. 1a, Supporting Information Fig. 1A ). Increased MUC13 expression in ccRCC was validated by Western immunoblot (patient cohort 2) and qRT-PCR on an independent patient set (patient cohort 3; Figs. 1b and 1c). We next expanded this MUC13 expression study to 110 distinct ccRCC patients using human tissue microarrays (patient cohort 4). MUC13 had a heterogeneous staining pattern in ccRCC, both within and between individual cancers. MUC13 was expressed in 107/110 (96%) cases of ccRCC with a predominantly diffuse cytoplasmic staining, with a minority of the cases (23/110 (20%) showing additional membranous immunoreactivity. Foci of cells staining with MUC13 were often observed in low grade cancers (Fig. 1d) , whereas in high grade cancers there was frequently strong cytoplasmic expression of MUC13 (Fig. 1d) . Using a semi quantitative score, we found that the cytoplasmic MUC13 staining score (intensity plus proportion) was significantly increased in grade III and IV tumors, compared to grade I and II tumors (Fig. 1e) . Together, these results suggest that MUC13 is aberrantly expressed with loss of polarization in ccRCC, and its overexpression is associated with aggressive disease whereas in normal kidney, MUC13 is present only in the collecting duct and distal tubule epithelium.
High MUC13 expression in clear cell RCC is associated with poor survival
To further determine the association of MUC13 expression with clinical outcomes, we analyzed MUC13 IHC staining on tissue microarrays from two distinct cohorts (cohorts 4 and 5). Relative cytoplasmic MUC13 expression in tumor tissues from the patients was classified into two groups: low-MUC13 (low relative levels of MUC13, staining scores 4) and high-MUC13 (high relative levels of MUC13, scores 5). Longterm survival data was available from 35 ccRCC patients in Cohort 4. High-MUC13 was significantly associated with poor overall survival, with a 10-year survival of 35% compared to 91% in the low-MUC13 expression group (p 5 0.011, Fig. 2a ). Fig. 2b ). MUC13 expression did not influence survival in later stage tumors (n 5 22), and while the numbers of late stage tumors was small, the curves were overlapping. Taken together, these findings demonstrate that MUC13 overexpression is a prognostic marker for overall survival of ccRCC patients, particularly for early stage tumors.
MUC13 overexpression in non-clear cell RCC
We next examined MUC13 expression in less prevalent histologic types of RCC, including papillary and chromophobe carcinomas. Of these 14 patients (patient cohort 4), 12 (86%) overexpressed MUC13. All eight papillary RCC showed medium to strong diffuse cytoplasmic MUC13 staining (Supporting Information Figs. 2A and 2B ). MUC13 expression was observed in 4 out of 6 chromophobe RCC (66%) (Supporting Information Figs. 2C and 2D ). Thus, MUC13 is expressed in all major histologic types of RCC.
MUC13 promotes proliferation and migration of RCC cells
To investigate the biological role of MUC13 in renal cancer, we first checked the expression of MUC13 in several ccRCC cell lines, including 769-P, 786-O, A498, A704, ACHN and Caki-1. With the exception of Caki-1 cells, all cell lines endogenously expressed MUC13 (Fig. 3a) . To explore the effects of MUC13 silencing we utilized two independent sets of siRNAs to control for potential off-target effects. Each set of MUC13 siRNA resulted in a 68-88% reduction in MUC13 mRNA expression and protein levels 48 hr post-transfection, compared to cells transfected with control siRNA (Fig. 3b) . siRNA silencing of MUC13 with either siRNA resulted in a significant decrease in cell proliferation, as measured by cell growth in real-time using an IncuCyte FLR analyzer (Fig. 3c,  Supporting Information Fig. 3A ). Further supporting a growth promoting role, overexpression of MUC13 in HEK293 cells (Fig. 3b ) enhanced their proliferation (Fig. 3c) . In addition, MUC13 also promoted clonogenic potential of all cell lines as determined by colony formation assays (Fig.  3d, Supporting Information Fig. 3B ). Because similar results were observed with the different siRNA's (Supporting Information Figs. 3A and 3B), one MUC13 siRNA (#1 -SMART pool) was used in all subsequent experiments. Cell migration has an important role in cancer metastasis. In wound-healing experiments, we observed a marked inhibition of cell migration in 769-P and ACHN cells upon MUC13 siRNA silencing (Fig. 3e, Supporting Information Fig. 3C ). The analysis of 769-P, 786-O and A498 cell invasion also demonstrated MUC13 siRNA silencing significantly decreased the invasive properties of these tumor cells (Fig. 3f , Supporting Information Fig. 3D ). Taken together, these in vitro findings align with our clinical data associating high MUC13 expression with tumor progression and poor survival. Because another cell surface mucin, MUC1, has previously been shown to influence RCC growth 33 we checked MUC1 expression by flow cytometry in 769-P and 786-O cells and could not find MUC1 cell surface expression by flow cytometry with BC2 antibody or altered protein level of MUC1 by western blot with CT2 antibody either before or after MUC13 silencing demonstrating the specificity of our findings for MUC13 (Supporting Information Fig. 4 ).
Silencing of MUC13 sensitizes RCC cells to treatment with multi-kinase inhibitors
Given the importance of MUC13 in promoting tumorigenic properties of RCC, we investigated the effect of combining the multi-kinase inhibitors, sorafenib and sunitinib, and silencing of MUC13 in 769-P and 786-O cells. We first silenced MUC13 with siRNA, treated the cells with sorafenib or sunitinib, and measured cell growth, migration and apoptosis using real-time imaging and flow cytometry. Consistent with previous results, MUC13 silencing slowed proliferation and migration, and increased apoptosis, however, in combination with sorafenib or sunitinib, silencing MUC13 more substantially impaired cell proliferation and migration, and greatly enhanced cell death (Figs. 4a-c) . These data show that MUC13 silencing sensitizes cultured RCC cells to multi-kinase inhibitors used clinically, making it a potential important target for adjuvant treatment in RCC.
MUC13 promotion of cell growth and migration is largely dependent on activation of NFjB
We next sought to determine the mechanisms by which MUC13 might govern the biology of RCC cells. To this end, we examined the effect of MUC13 silencing on growth signalling and survival pathways. Western Blot analysis revealed that knockdown of MUC13 alone, or in combination with sorafenib or sunitinib, decreased NFjB p65 phosphorylation, whereas exposure to sorafenib or sunitinib in the presence of MUC13 enhanced NFjB p65 phosphorylation in control siRNA-treated cells (Fig. 5a ). We also examined the effect exerted on expression of proteins that regulate growth and apoptosis that are known to be downstream of NFjB. The levels of BCL-xL, survivin and cyclin D1 increased in response to sorafenib and sunitinib, and this was not seen in MUC13-silenced cells (Fig. 5a ). These data suggest that a potential mechanism by which MUC13 enhances RCC tumor progression is via activation of NFjB and its downstream regulated gene expression. Underlining the mechanism of MUC13 action via NFjB, treatment of RCC cells with a functional inhibitor of NFjB, Bay 11-7085 (Bay), impaired survival in cells expressing MUC13 and no further effect on survival was seen when MUC13 was silenced. Interestingly, in 769-P cells pharmacological inhibition of NFjB and MUC13 silencing had equivalent effects, whereas in 786-O cells NFjB inhibition affected growth and survival to a greater degree than MUC13 silencing (Fig. 5b) . We also compared migration after MUC13 silencing and/or NFjB inhibition. The NFjB inhibitor (plus control siRNA) slowed migration, being equally as effective as MUC13 siRNA in 786-O cells, with a strongly synergistic effect of the combination, and less effective than MUC13 silencing in 769-P cells (Fig. 5c ). Silencing of MUC13 impairs cell growth and survival in sorafenib and sunitinib resistant cells
We next speculated whether MUC13 siRNA treatment could overcome resistance in sorafenib and sunitinib resistant human RCC cells. For this purpose, we established resistant sublines (769-P sorR and 769-P sunR) from the parental 769-P cell line by eight months of culture in 2 mM sorafenib or sunitinib. 769-P sorR and 769-P sunR cells exhibited higher growth rates than the parental cells (Fig. 6a) . Both resistant cell lines were unaffected by a higher dose (7 lM) of either drug (Fig. 6b) . However, silencing MUC13 in 769-P sorR and 769-P sunR cells substantially impaired cell growth and survival (Fig. 6b) . Furthermore, silencing MUC13 restored sensitivity of both resistant cell lines to sorafenib or sunitinib, as evidenced by a decrease in cellular metabolism (MTT assay; Fig. 6b ) and increased cell death (flow cytometry; Fig. 6c ). Pharmacological inhibition of NFjB was less effective in 769-P sorR and 769-P sunR cells at inhibiting growth and survival than in parental cells (Fig. 6d) , but MUC13 silencing remained effective.
Because the reduced effectiveness of the NFjB inhibitor may be attributable to enhanced drug efflux in the resistant cells and given the association between MUC13 and NFjB signalling, we next attempted to elucidate whether NFjB signalling in 769-P sorR and 769-P sunR cells and the development of resistance were dependent on MUC13. Western immunoblot analysis showed that NFjB phosphorylation was greater in the resistant cells compared to their parental cell line, together with increased levels of MUC13 and BCL-xL (Fig. 6e) . MUC13 silencing alone or in combination with sorafenib or sunitinib decreased the expression of phosphorylated NFjB p65 and BCL-xL (Fig. 6f) . In addition to activation of NFjB pathway, we also observed that ATP-binding cassette (ABC) transporter B1 (ABCB1 or MDR1) protein which effluxes drugs was induced by chronic sorafenib or sunitinib treatments and dependent on MUC13 expression (Fig. 6f) . Consistent with upregulation of MDR expression, chronic sorafenib or sunitinib treatments also induced resistance to a cytotoxic drug that is a MDR substrate, docetaxel, and this resistance was also dependent on MUC13 expression (Supporting Information Fig. 5 ). Taken together, these data show that MUC13 is increased by sorafenib and sunitinib resistance and essential for several growth and survival mechanisms, including expression of drug efflux proteins.
Discussion
Clear cell RCC has a high metastatic rate and represents a significant and difficult-to-manage disease. Our findings with respect to the expression and function of MUC13 in ccRCC open opportunities to address several of the major challenges presented by this cancer; providing a new prognostic indicator for early stage disease and a novel therapeutic target to sensitize tumors to therapy even after the development of drug resistance.
MUC13 is expressed by virtually all RCC, with high expression positively correlated with tumor grade and poor prognosis, suggesting that MUC13 is a promising biomarker for predicting progression. High levels of MUC13 were associated with shortened survival time, particularly for patients with TMN stage 1 disease. Thus, we propose high MUC13 expression as a prognostic biomarker for better individual risk stratification. This could identify patients who need to receive adjuvant therapy and intense follow-up after surgery; even if they are low risk according to the traditional clinicopathologic analyses. TNM staging is currently the only established pathological prognostic marker for RCC, however, despite its importance and it being widely used, there will still be questions about the validity and prognostic ability of this system alone. Therefore, MUC13 will be a promising candidate to predict the clinical outcome in patients with RCC and to select patient subgroups, which might benefit from a more personalized medicine. To translate these findings into a clinically relevant tool, further prospective studies in larger cohorts are needed and should be a priority. The association of MUC13 with poor survival bears similarity to previous findings that overexpression of MUC1 is associated with high grade, metastatic progression and poor survival in stage 1 ccRCC. 34 Relatively high MUC1 expression has also been reported in type 1 papillary renal cancers, although this was not associated with poorer survival. 35 Together with our findings this suggests that the cell surface mucin family is broadly involved in promoting RCC progression, explaining why these glycoproteins are commonly overexpressed by epithelial tumors. Although we demonstrate in vitro strong effects of MUC13 independent of MUC1, the relative and combined importance (where co-expressed) of these two mucins in RCC is worthy of further investigation.
In addition to the level of expression, we also observed that the pattern of immunostaining for MUC13 is different in tumor cells and normal renal tubule cells. This is also a feature of MUC13 in other cancers, where cytoplasmic accumulation of MUC13 is associated with more aggressive tumors. 23, 30 Furthermore, we show that MUC13 promotes RCC cell growth, migration and anti-apoptotic programs, consistent with previous findings regarding MUC13 in colorectal, 21 pancreatic 24, 25 and ovarian 26 cancers, and explaining the relationship with poor survival.
RNAi silencing of MUC13 resulted in substantially decreased cell proliferation, colony formation, migration and invasion, while overexpression promoted cell growth and colony formation. In addition, MUC13 silencing sensitized renal cancer cells to sorafenib or sunitinib, and inhibited tumor cell migration. These findings raise the possibility that targeting MUC13 expression or function could sensitize RCC to a range of therapies, providing a new molecular target which could be combined with multiple other modalities. The development of strategies for prolonging the effects of sorafenib or sunitinib and other agents is particularly important in metastatic RCC, since these tumors typically develop resistance to Tumor Markers and Signatures therapy within 5-11 months. In elucidating the biological mechanisms by which MUC13 promotes renal cancer development, we identified similar mechanisms to those recently described in colorectal cancers. MUC13 promotes activation of the NFjB signalling pathway in RCC cells. NFjB is a central player in the behaviour of cancer cells from many types of adenocarcinoma, including RCC. NFkB promotes epithelial cancer cell growth and survival through activation of several target genes such as cyclin D1, BCL-xL and survivin, which in turn promote proliferation and/or block apoptosis. NFjB inhibition had a potent effect on the RCC cells and the influence of MUC13 on cell growth/survival was lost. Targeting NFjB directly is problematic because of its many roles in normal cells and therefore MUC13 provides a target which phenocopies NFjB inhibition but has greater tumor specificity. These data further strengthen a model in which MUC13-induced cell proliferation, migration and inhibition of apoptosis is mediated through the NFjB pathway across multiple cancer types.
Sunitinib has been shown to effectively inhibit neovascularization and produce antitumor effects, but in mice with pancreatic neuroendocrine tumors, adaptation to sunitinib can lead to development of increased invasion and metastasis. 36 Consistent with this preclinical finding, the majority of patients who receive sunitinib for advanced ccRCC exhibit progressive disease within one year of treatment. 37 We show that chronic exposure to sunitinib or sorafenib promoted RCC cell growth and developed drug resistance. This drug resistance was associated with increased expression of MUC13, and both resistant sublines remained sensitive to MUC13 silencing, with increased cell death and inhibition of proliferation. These findings suggest that MUC13 is an important mediator of drug resistance and that MUC13 remains a viable target in drug resistant cancers.
The mechanism of MUC13 silencing in reducing resistance to standard anti-angiogenic therapeutic agents may be multifactorial. The effect of MUC13 in promoting drug resistance may be attributed to its ability to drive NFjB activation which has previously been shown to be a regulator of the drug transporter pump ABCB1/MDR1. This pathway provides a mechanism additional to effects on proliferation and apoptosis by which the MUC13-NFjB axis promotes resistance to therapy. We believe selective inhibition of MUC13 expression is a promising strategy. Minimal side effects have been demonstrated in treating colorectal cancer 30 and inhibition of MUC13 may also prove effective in ccRCC. Here, we report for the first time that MUC13 silencing in combination with sorafenib and sunitinib, current therapy for RCC, not only enhances the sensitivity of na€ ıve RCC cell lines to sorafenib and sunitinib, but also reverses sorafenib and sunitinib resistance in resistant cell lines. We provide the rationale and experimental evidence for the combined use of MUC13 antagonism and sorafenib or sunitinib to potentially limit and overcome drug resistance in patients with MUC13-overexpressing RCC. In conclusion, these data suggest that MUC13 may be a useful prognostic biomarker and potential therapeutic target in RCC, with the potential to lead to better outcomes for patients with these poor prognosis malignancies.
